Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________ Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-33462 ___________________________________________________________ INSULET CORPORATION (Exact name ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-36313 METALLUS INC. (Exact name of registrant as specified in its charter) | | | (State or other jurisdiction of incorporation or organi ...

Financial Performance - Net sales for Q3 2025 were $305.9 million, an increase of $78.7 million, or 34.6% compared to Q3 2024, driven by higher shipments and favorable surcharges [84]. - For the nine months ended September 30, 2025, net sales were $891.0 million, an increase of $47.5 million, or 5.6% compared to the same period in 2024, primarily due to higher shipments and surcharges [87]. - Gross profit for Q3 2025 increased by $22.9 million, or 189.3% compared to Q3 2024, attributed to higher volume and favorable raw material spread [90]. - Base sales for the three months ended September 30, 2025, were $241.9 million, up from $182.0 million in the same period of 2024, reflecting a growth of approximately 32.8% [106]. - The company reported a total of 163.1 thousand ship tons for the three months ended September 30, 2025, compared to 119.9 thousand ship tons for the same period in 2024, indicating a 36.0% increase in shipment volume [106]. Expenses and Investments - SG&A expenses for Q3 2025 rose by $2.0 million, or 8.9%, compared to Q3 2024, mainly due to higher variable compensation and salary [97]. - Capital investments for Q3 2025 were $28.4 million, with a total of $73.7 million for the nine months ended September 30, 2025, focusing on safety and equipment automation [79]. - Capital expenditures for 2025 are projected to be approximately $120 million, including about $90 million funded by the U.S. government [114]. - Net cash used by investing activities for the nine months ended September 30, 2025, was $44.0 million, compared to $3.6 million in the same period of 2024, due to higher capital expenditures [122]. Liquidity and Cash Flow - Total liquidity as of September 30, 2025, was $436.9 million, including cash and cash equivalents of $191.5 million [81]. - The company’s net cash provided by operating activities for the nine months ended September 30, 2025, was $17.9 million, down from $26.4 million in the same period of 2024, primarily due to increased working capital needs [121]. - Total liquidity as of September 30, 2025, was $436.9 million, slightly down from $458.6 million as of December 31, 2024 [112]. - The company expects to meet its working capital needs and other liquidity requirements for at least the next twelve months based on current cash balances and projected cash flows [113]. Share Repurchase and Taxation - The company repurchased 0.2 million and 0.9 million common shares for $3.0 million and $11.9 million in Q3 and the nine months ended September 30, 2025, respectively [81]. - The company repurchased approximately 0.9 million common shares at an aggregate cost of $11.9 million during the nine months ended September 30, 2025, with an average repurchase price of $14.31 per share [118]. - The effective tax rate for Q3 2025 was 25.7%, up from 16.9% in Q3 2024, primarily due to being in a taxable income position [100]. Government Funding and Support - The company received $10.0 million and $28.0 million from the U.S. government in Q3 and the nine months ended September 30, 2025, respectively, as part of a $99.75 million funding agreement [79]. Market and Economic Conditions - The company is closely monitoring trade developments, including tariffs on steel imports, which are expected to positively impact demand for domestic products [81]. - The company is monitoring the impacts of global economic conditions, including potential slowdowns and political risks in regions where it operates [129]. - The company emphasizes the uncertainty of future results due to various factors, including customer demand fluctuations and economic conditions [126]. - The company is cautious about the potential impacts of pandemics and health issues on its operations [129]. Strategic Focus and Goals - The company is focused on achieving its 2030 environmental goals, which may be impacted by changes in regulations and technology adoption [129]. - The company is focused on improving profitability through strategic actions and initiatives [126]. - The company is investing in equipment to support the U.S. Army's munitions production, contingent on timely funding and successful installation [129]. - The company is assessing the availability of financing and interest rates, which could affect its capital-raising capabilities [129]. - The company faces competitive pressures from both domestic and foreign competitors, including price competition and new product introductions [129]. - The company is committed to maintaining appropriate relations with unions to avoid business disruptions [126].

"We are pleased with the strength of our overall results and continued progress throughout the company," commented Keith Pfeil, President and Chief Executive Officer. "Q3 revenue rose 23%, driven by 10% growth in our US Spine business, as momentum accelerated during the quarter with broad based demand across our products and geographies. Our recently acquired Nevro business continued to exceed expectations, underscoring the strength of our integration strategy, as we position this business for future growth ...

Exhibit 99.1 Eton Pharmaceuticals Reports Third Quarter 2025 Financial Results DEER PARK, Ill., November 6, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or "the Company") (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended September 30, 2025. "The third quarter was another stellar period for Eton with product sales growing 129% year over year. The impressive results c ...

Financial Performance - Net sales for the first quarter of fiscal 2026 were $81.6 million, a decrease of $3.5 million, or 4.1%, compared to the first quarter of fiscal 2025[10] - Gross profit was $32.4 million, representing a gross margin of 39.7%, down from 43.9% in the same quarter last year[10] - The company reported a net loss of $4 million for the first quarter of fiscal 2026, an improvement from a net loss of $5 million in the first quarter of fiscal 2025[10] - Adjusted EBITDA remained flat at $1.4 million for both the first quarter of fiscal 2026 and the first quarter of fiscal 2025[10] - Operating expenses decreased to $35.6 million, or 43.6% of net sales, compared to $40.1 million, or 47.2%, in the first quarter of fiscal 2025[10] - Net loss for the three months ended September 30, 2025, was $4,025,000, an improvement from a net loss of $5,002,000 in the same period of 2024[20] - EBITDA for the same period was $(751,000), compared to $(1,408,000) in 2024, resulting in an EBITDA margin of (0.9)%[26] - Adjusted EBITDA for the three months ended September 30, 2025, was $1,364,000, consistent with an Adjusted EBITDA margin of 1.7%[28] Cash Flow and Assets - The company had $3.8 million in unrestricted cash and cash equivalents as of September 30, 2025[5] - Cash flows from operating activities showed a net cash used of $5,007,000, a decline from net cash provided of $2,493,000 in 2024[20] - Cash and cash equivalents at the end of the period were $3,999,000, down from $5,138,000 at the end of the same period in 2024[20] - The company experienced a net decrease in cash and cash equivalents of $2,975,000, compared to a decrease of $867,000 in the prior year[20] - As of September 30, 2025, total assets were $158.8 million, a decrease from $161.2 million as of June 30, 2025[18] Strategic Initiatives - Farmer Brothers announced a partnership with Eurest to open 50 Sum>One Coffee Roasters-branded cafes across the country[10] - The company maintained a focus on driving top-line revenue and customer growth in 2026 despite a challenging economic environment[3] - The company incurred $587,000 in strategic initiative costs during the quarter, which were not present in the previous year[28] Expenses - There was a nearly $4 million improvement in sales, general, and administrative (SG&A) expenses compared to the first quarter of fiscal 2025[10] - Depreciation and amortization expense for the quarter was $2,614,000, compared to $2,897,000 in 2024[26] - The company reported a net cash used in investing activities of $1,919,000, an improvement from $3,304,000 in the prior year[20] - Proceeds from credit facilities amounted to $4,000,000, compared to $3,000,000 in the same period of 2024[20]

RANCHO CUCAMONGA, CA – November 6, 2025 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) ("Amphastar" or the "Company"), a biopharmaceutical company focused on developing, manufacturing, and marketing complex generic and proprietary injectable, inhalation, and intranasal products, today reported results for the three months ended September 30, 2025. "Amphastar delivered another strong quarter, led by double-digit growth from BAQSIMI®, which achieved a 14% increase in revenue compared to the same period last ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-11919 TTEC Holdings, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (I.R ...

Our net income (loss) before interest expense, income taxes and depreciation and amortization expense (EBITDA) (see description of non-GAAP information below) in the third quarter of 2025 was $.6 million compared to EBITDA of $123.3 million in the third quarter of 2024. For the first nine months of 2025, our EBITDA was $74.0 million compared to EBITDA of $211.2 million in the first nine months of 2024. EBITDA comparisons for the three and nine months ended September 30, 2025 and 2024 were affected by non-ca ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________________________________________________ FORM 10-Q ___________________________________________________________________________________________ (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For ...